The Board of Directors of Immunovia proposes a reverse share split
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The Board of Directors of Immunovia AB (publ) (“Immunovia” or the ”Company”) proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio 1:100, resulting in hundred (100) shares being consolidated into one (1) share (the ”Reverse Share Split”). Notice of the Extraordinary General Meeting will be published through a separate press release.
Reverse Share Split
The Board of Directors of Immunovia proposes that an Extraordinary General Meeting resolves to carry out the Reverse Share Split, in the ratio 1:100, resulting in hundred (100) shares being consolidated into one (1) share. The reason for the Reverse Share Split is that the Company wants to achieve an appropriate number of shares for the Company.
If a shareholder's holding of shares does not correspond to a full number of new shares, the excess shares will become the property of the Company on the record date for the Reverse Share Split. Excess shares will then be sold at the Company's expense by Vator Securities AB, whereby the shareholders concerned will receive their share of the sales proceeds. The Reverse Share Split will be effected automatically via Euroclear Sweden AB and shareholders do not need to take any action. Further information on the procedure for the Reverse Share Split will be published in connection with the Board of Directors' resolution on the record date.
Following the Reverse Share Split, the number of shares in the Company will decrease from 672,666,892 to 6,726,668 (rounded downwards). At the same time, the proposed Reverse Share Split will increase the quota value of the share from SEK 0.03 to approximately SEK 3.00.
Extraordinary General Meeting
The Board of Directors’ proposal on the Reverse Share Split is subject to approval by the Extraordinary General Meeting on 22 January 2026. The Extraordinary General Meeting is also proposed to resolve on an amendment of the Articles of Association to enable the Reverse Share Split. Notice of the Extraordinary General Meeting will be published through a separate press release.
Indicative timetable for the Reverse Share Split
The following indicative timetable, which is subject to change based on lead time for registrations etc., applies to the Reverse Share Split:
| Date | Action |
| 22 January 2026 | Extraordinary General Meeting. |
| 27 January 2026 | Resolution on the record date for the Reverse Share Split. |
| 2 February 2026 | Last day of trading in the Company's share before the Reverse Share Split. |
| 3 February 2026 | First day of trading in the Company's share following the Reverse Share Split. As of this date, the share price reflects the effect of the Reverse Share Split. |
| 4 February 2026 | Record date for the Reverse Share Split. |
| 5 February 2026 | The new number of shares is expected to be registered in each shareholder's VPC account. |
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
The information was submitted for publication, through the agency of the contact person set out above, on 17 December 2025 at 17:10 CET.
Immunovia in brief
Immunovia is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.